Coronavirus, Pfizer relaunches: vaccine 95% effective
Coronavirus, Ema begins Modern vaccine approval process.
The company: "94.5% effective"
EU, we are treating 160 million vaccine doses with Moderna.
Company: contract delay will slow distribution
Share
November 19, 2020 The vaccine against Covid-19 developed by the company AstraZeneca in collaboration with the University of Oxford produces a "strong immune response in the elderly".
This is what emerges from the data of the first studies published in the medical journal The Lancet.
The results of phase one and phase two suggest that one of the groups most at risk of death or serious illness from Covid-19 is able to build immunity.
About 560 healthy adult volunteers took part in phase two tests, in which they were given two doses of the vaccine candidate, or a placebo.
No serious side effects were reported, the report reads.
"Immune responses to vaccines are often decreased in the elderly because the immune system gradually deteriorates with age, which also makes the elderly more susceptible to infections. Consequently, it is imperative that Covid-19 vaccines are tested in this group. which is also a priority group for immunization, ”explained the study's lead author, Professor Andrew Pollard, of the University of Oxford, UK.
"The robust antibody and T-cell responses seen in older people in our study are encouraging. Populations at greatest risk of serious Covid-19 disease include people with past health problems and older adults. We hope this means the our vaccine will help protect some of society's most vulnerable people, but more research will be needed before we can be sure, 'explained co-author Dr Maheshi Ramasamy, of the University of Oxford.